A highlight of the year was the FDA approval of ZYCUBO® (copper histidinate) for the treatment of Menkes disease, which was followed by the successful sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million by Fortress's subsidiary, Cyprium Therapeutics. This transaction not only provided immediate capital but also positioned Cyprium to receive tiered royalties and potential sales milestones from Sentynl Therapeutics, further enhancing Fortress's revenue streams.
Additionally, Fortress's subsidiary Checkpoint Therapeutics was acquired by Sun Pharmaceutical Industries, generating significant upfront capital and establishing a long-term royalty stream from the approved drug UNLOXCYT™ (cosibelimab-ipdl). This acquisition underscores Fortress's strategic focus on monetizing its assets and advancing high-value clinical programs.
The company also reported a consolidated cash position of $79.4 million as of December 31, 2025, reflecting a solid liquidity position despite a decrease from $86.2 million at the end of the previous quarter. Fortress's leadership, led by Chairman and CEO Lindsay A. Rosenwald, M.D., emphasized the disciplined execution across its portfolio, highlighting the successful monetization of assets and the advancement of clinical programs as key drivers of value for shareholders.
Looking ahead, Fortress is optimistic about its strategy to build diversified revenue streams and create long-term shareholder value. The progression of its clinical programs, including the advancement of dotinurad into Phase 3 trials, further supports this outlook. The company remains committed to leveraging its biopharmaceutical expertise and partnerships to maximize the potential of its product opportunities.
